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HMEC = human mammary epithelial cells; hTERT = catalytic subunit of the telomerase enzyme.
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Introduction
The advent of spatially and temporally regulated transgen-
ics has allowed a careful dissection of the independent
roles of oncogenes and tumor suppressors to the series of
events governing initiation, progression and maintenance
of tumorigenesis [1]. A surprising theme from these types
of studies has been the finding that a single oncogene
may drive tumor development, often with an invasive phe-
notype, but that withdrawal of the initiating oncogene may
lead to complete tumor regression. The recent findings
from the laboratory of Lewis Chodosh reveal that
mammary-targeted expression of the c-Myc oncoprotein is
sufficient for the induction of mammary tumorigenesis, and
that withdrawal of the oncogenic stimulus results in tumor
regression [2]. Previous studies with antisense oligonu-
cleotides directed against c-myc mRNA (and other onco-
genes) caused tumor regression, consistent with the
model in which maintenance of tumorigenesis can be sus-
tained through expression of a single oncogene. The rapid
regression of invasive mammary tumors on withdrawal of
mammary-targeted transgenic c-Myc expression [2] is
consistent with a growing body of evidence that oncogene
expression may be sufficient for the induction of but not
the maintenance of tumorigenesis [3–6].
Oncogenic H-Ras (Val12®Gly12) under control of the
reverse tetracycline transactivator targeted by the tyrosi-
nase gene promoter in the p16INK4+/– background induces
melanomas [4]. Tumors regressed on withdrawal of H-Ras
(Val12®Gly12), although approximately one-third devel-
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Breast cancer arises from multiple genetic events that together contribute to the established,
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second mutation within the Ras pathway.
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oped recurrence of phenotypically distinct neoplasms [4].
Targeting tamoxifen-inducible c-Myc expression to the
suprabasal epidermis under control of the Involucrin pro-
moter induced papillomatosis with angiogenesis that was
reversible on withdrawal of c-Myc expression [6]. Higher
levels of c-Myc expression correlated with more rapid
development of the phenotype, and vascular endothelial
growth factor production induced by c-Myc was postu-
lated to contribute an in vivo paracrine survival signal [6].
Tetracycline-regulated c-Myc, targeted to the hematopoi-
etic compartment under control of the immunoglobulin
heavy chain enhancer, induced T cell lymphomas and
acute myeloid leukemia that remitted on withdrawal of Myc
expression [5]. In the 10% of mice in which relapse
occurred, tumors had either escaped conditional regula-
tion by the tetracycline system or had undergone a
presumed secondary genetic event. Felsher and Bishop
proposed that the genomic instability induced by c-Myc
itself might have facilitated the accumulation of tumori-
genic mutations [5].
Myc and collaborative oncogenesis
The current studies underscore the importance of collabo-
rative oncogenes in Myc-induced tumorigenesis. In the
studies by D’Cruz et al, tetracycline-regulated induction of
c-Myc expression in the mammary epithelium induced
mammary tumorigenesis rapidly, within 22 weeks, and
with high penetrance (86%). The T50 value for mammary
tumor occurrence in MMTV-Ha-Ras (T50 = 168 days) and
MMTV-c-Myc (T50 = 325 days) was accelerated in the
presence of both transgenes (T50 = 46 days) in previous
in vivo studies [7]. Furthermore, the Ras transgene abro-
gated the requirement for pregnancy in c-Myc-induced
mammary tumor onset [7,8]. Myc collaborates with a
variety of signaling pathways, including Ras, Bcl-2, a tran-
scriptional repressor in the polycomb family (Bmi-1),
Notch,  twist, and factors that inactivate p53. Suppression
of apoptosis enables oncogenes such as c-myc and E1A
to acquire full oncogenic activity [9]. In primary mouse
embryo fibroblasts, c-Myc-induced apoptosis requires
CD95 (Fas/APO-1), Apaf-1 and Caspase 9. Insulin-like
growth factor-1 signaling and Bcl-2 suppress Myc-
induced apoptosis, and bcl-2 overexpression suppressed
c-Myc transgene-induced apoptosis and accelerated
mammary tumorigenesis. Since Myc induces apoptosis, it
has been predicted that collaborative oncogenesis may
occur with pathways that selectively inactivate Myc-
induced apoptosis. For example, c-Myc-induced apoptosis
is dependent on the induction of 19ARF [10], and the
strong collaboration in oncogenesis between the Em-Myc
and Bmi-1 involves the downregulation of INK4A/ARF.
Several different types of collaborative interactions
between Ras and Myc are known. Ras fails to inhibit Myc-
induced apoptosis in fibroblasts, although growth factor
rescue of c-Myc-induced apoptosis may occur in epithelial
cells through the Ras-mediated induction of Akt phospho-
rylation [11–13]. Myc is induced by proliferative signals,
and the serum-induced increase in the Myc half-life is
mediated by Ras activation through Raf/ERK and Akt
pathways [14].
How might oncogenic Ras contribute to ongoing tumorige-
nesis? The important and exciting new observation made
by D’Cruz et al [2] was that almost one-half of the c-Myc-
induced mammary tumors harbored point mutations in the
K-ras or N-ras gene. Furthermore, there was a significant
correlation between the presence of point mutations in the
ras gene and the persistence of tumorigenesis following
downregulation of transgenic c-Myc expression, suggest-
ing that maintenance of mammary tumorigenesis involves a
second mutation with the Ras pathway. Oncogenic Ras is
known to contribute both cell nonautonomous tumor–host
interactions and cell autonomous activities. Ras may confer
the ability to evade the host immune response and sustain
tumor cell vasculature through regulating vascular endothe-
lial growth factor expression. The maintenance of tumor
growth by H-Ras (Val12®Gly12) in an inducible in vivo
melanoma model suggested a role for both cell
autonomous functions of Ras in tumor maintenance and a
role for the induction of vascular endothelial growth factor
expression. However, this was not sufficient to overcome
tumor regression [4]. Transformation by Ras can only
proceed in the presence of additional mutations that
prevent Ras-induced senescence. Myc and E1A inactivate
cellular responses that are required for Ras-mediated inhi-
bition of cellular proliferation.
Human mammary epithelial cells and
maintenance of transformation.
What is the relevance of these studies to human breast
cancer? The majority of human breast cancers also arise
from mammary epithelia, and c-Myc is found amplified
(15%), rearranged (5%) and overexpressed in about 70%
of cases, suggesting an important role in genesis or pro-
gression of breast cancer [1,15]. Signaling via the
retinoblastoma protein (pRB) pathway is frequently inacti-
vated either through overexpression of cyclin D1 or loss of
expression of either the pRB or p16Ink4a. Mutations in the
p53/ARF tumor suppressor pathway occur in up to one-
half of all tumors. Alterations in the Ras signaling pathway,
mediated through amplification or overexpression of the
ErbB2/Neu gene, are found in up to 30% of patients. This
perhaps explains the low frequency of ras gene mutations
found in human breast cancers. At a more fundamental
level, however, rodent cells can be transformed through
concomitant expression of two oncogenes, whereas
immortalization of human epithelial cells has additional
requirements [16]. Myc is sufficient for the partial transfor-
mation of both mouse and human mammary epithelial
cells, growing on soft agar in response to epidermal
growth factor. Human fibroblasts [16] or human mammary
epithelial cells (HMEC) can be transformed through thec
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coexpression of oncogenic Ras (H-rasV12), the SV40
large T and the catalytic subunit of the telomerase enzyme
(hTERT) [17]. Consistent with the importance of Ras
found in the studies from the laboratory of Lewis Chodosh,
an important correlation was previously found between the
level of Ras oncogene expression and the tumorigenicity
of the HMEC. Intriguingly, the HMEC transformed in this
manner expressed amplified c-Myc [17], emphasizing an
important inter-relationship between Ras and c-Myc in the
transformation of HMEC. An intriguing question remains
as to what role hTERT is playing in in human breast
cancer. hTERT is the catalytic subunit of the telomerase
enzyme. HMEC that emerge from senescence exhibit
eroding telomeric sequences and ultimately enter telom-
ere-based crisis to generate the types of chromosomal
abnormalities seen in the earliest lesions of breast cancer
[18]. hTERT overexpression in human cells prior to senes-
cence induces indefinite cellular proliferation, although
there may not always be a corresponding lengthening of
the telomeres [19].
How might Myc overexpression contribute to the induction
of mutations within the ras gene? The current studies by
D’Cruz et al identify another potentially important mecha-
nism for collaboration between c-Myc and Ras, and raise
the strong possibility that these events may be required for
the maintenance of rather than simply induction of tumori-
genesis: the induction by c-Myc of activating mutations
within the K-ras2 gene. The high prevalence of the ras
gene mutations and the identification of similar mutations
in other models of c-Myc-induced mammary tumorigenesis
suggest c-Myc overexpression may be causal in these
mutagenic events. The induction of Ras mutations may be
a consequence of c-Myc-induced genomic instability.
c-myc and several other oncogenes have been shown to
play a role in driving genomic instability [20,21]. Spectral
karyotyping has revealed that chromosomal abnormalities
are common in c-Myc-induced lymphomas and that tran-
sient c-Myc expression is sufficient for the induction of
genomic instability. c-Myc may contribute to genomic
instability by shortening the G1 to S phase transition. The
mechanism by which c-Myc triggers G1 exit is in part
through promoting increased cell mass, enhancing G1
cyclin/CDK activity, and by negatively modulating abun-
dance [22] and function [23] of the cell cycle inhibitor
p27Kip1. Forcing cells through the cell cycle in the pres-
ence of local DNA damage may inhibit expression of
genes involved in cell-cycle transition, or may titrate co-
activators that normally subserve functions regulating
genomic stability. The role of c-Myc-induced telomerase
activity in regulating genomic instability is unclear at this
time. Ectopic expression of c-Myc activates telomerase in
HMEC [24,25] and, conversely, hTERT overexpression
selects for c-Myc overexpression that may be anticipated
to thereby contribute to genomic instability [24,25]. Sur-
prisingly, hTERT-transduced HMEC overexpressing c-Myc
had a normal chromosome number. These findings
together suggest that, although capable of extending the
life span of HMEC, hTERT is not ‘genoprotective’.
Conclusions
The past decade has seen important progress in the
development of temporally regulated transgenics. The
careful molecular dissection of the events regulating myc-
dependent multistep mammary tumorigenesis, by the labo-
ratory of Lewis Chodosh, has uncovered another
important insight into the events governing commitment to
tumorigenesis. The finding that activation of the Ras
pathway and overexpression of c-Myc play a role in tumor
commitment suggests that therapeutics targeting multiple
pathways may be beneficial. It is known that c-Myc inhibits
cellular differentiation, enhances progression through the
G1 phase of the cell cycle, activates apoptosis, induces
anabolism, increases genomic instability and increases
telomerase activity [26]. Important biological activities of
c-Myc require Myc Box II, the deletion of which abrogates
transrepression function, cell-cycle progression, cofactor
TRRAP binding and transformation in cultured cell
systems. The use of transgenics targeting c-Myc mutants
proficient in cell-cycle progression but deficient in apopto-
sis [27] may provide important insights into the role of
apoptosis in c-Myc-induced tumor onset and progression.
Identifying the molecular mechanisms by which c-Myc
contributes to the separable functions of tumor induction
versus maintenance will be of great interest in the future.
The studies of D’Cruz et al suggest that determining the
mechanisms by which c-Myc regulates genomic instability
may help us to understand events leading to irrevocable
commitment to mammary tumorigenesis.
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